Omeros Corp.’s (OMER) Narsoplimab, proposed for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy, awaits the FDA decision on October 17, 2021.Hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) is a lethal complication of stem cell transplantation caused by endothelial cell damage, which is induced by conditioning regimens, immunosuppressant therapies, infection, graft-versus-host disease, and other factors associated with stem cell transplantation.Currently there are no approved drugs for HSCT-TMA. If approved, Narsoplimab could achieve sales of $575 million globally in the indication of HCST-TMA by 2027, according to Global Data. (Source: Clinical Trials Arena).OMER closed Wednesday’s trading at $13.40, down 2.83%.